Smoking and Bone Health in Canada: The Evidence and What Quitting Can Do

Tobacco smoking is one of the most well-documented modifiable risk factors for osteoporosis. Current smokers have measurably lower bone density than non-smokers, fracture at higher rates, and heal more slowly when they do. The damage accumulates over years — but stopping smoking initiates a recovery process that continues for a decade or more.

How Common Is Smoking Among Canadians with Osteoporosis?

Canada's smoking rate has declined from about 25% in 2001 to roughly 11% today — one of the most successful public health trajectories in the world. But the existing population of long-term smokers and former smokers carries significant bone health consequences that will play out over the next 20–30 years in terms of fracture rates.

How Smoking Reduces Bone Density: The Mechanisms

Smoking damages bone through several overlapping biological pathways. Understanding these helps explain why the effects are cumulative and why recovery after quitting is gradual.

Estrogen Degradation

This is the primary mechanism in women. The liver enzymes that process nicotine and other tobacco compounds also accelerate the metabolism of estrogen — meaning smokers clear estrogen from their system faster than non-smokers. Because estrogen is one of the most important hormones for maintaining bone density (it suppresses bone resorption by limiting osteoclast activity), lower estrogen levels directly translate to faster bone loss. This effect is measurable even in premenopausal women who smoke: they have lower estrogen levels on average than non-smoking women of the same age.

Earlier and More Severe Menopause

Women who smoke reach menopause approximately 1–2 years earlier than non-smokers, on average. This extends the total years of estrogen-deficient bone loss. Combined with the lower estrogen levels during the reproductive years (above), a woman who has smoked for 20+ years may enter the postmenopausal bone loss phase earlier, at a lower baseline bone mass, than a non-smoker. Osteoporosis Canada identifies smoking as a compounding risk factor specifically in the context of menopause and bone health.

Direct Toxicity to Bone Cells

Cadmium — a heavy metal present in cigarette smoke — accumulates in bone tissue. Cadmium has been shown to directly damage osteoblasts (bone-forming cells) and disrupts calcium signalling within bone. Separate from hormonal effects, this represents a direct cellular toxicity that contributes to bone density loss. Blood cadmium levels in smokers are typically 4–5 times higher than in non-smokers.

Reduced Calcium Absorption

Nicotine reduces calcium absorption in the gut and increases urinary calcium excretion. Like with heavy alcohol use, this negative calcium balance forces the body to pull calcium from bone to maintain blood calcium levels. Studies have shown that smokers absorb approximately 10–15% less calcium from food and supplements than non-smokers, all else being equal.

Impaired Vitamin D Activation

Smokers have lower serum 25-hydroxyvitamin D levels than non-smokers. The reason is not fully understood but likely involves altered vitamin D metabolism and reduced outdoor activity. Lower vitamin D compounds the calcium absorption problem: without adequate vitamin D, the body cannot absorb calcium efficiently from the diet regardless of intake. Given that Canada already has a significant vitamin D gap from limited sun exposure (especially October through April), smokers face a double deficit.

Reduced Body Weight and Muscle Mass

Smokers tend to weigh less than non-smokers. While this may seem like a health benefit in other contexts, lower body weight means less mechanical loading on bones — and mechanical load is one of the most important stimuli for maintaining bone density. Lower muscle mass in smokers also contributes to reduced loading and fall risk.

The Menopause Multiplier

The interaction between smoking and menopause is significant enough that Osteoporosis Canada specifically flags it. During the first 5–7 years after menopause, women lose bone at an accelerated rate (1–3% per year at the spine, compared to 0.3–0.5% per year before menopause). Smokers enter this phase with:

• Lower baseline bone mass accumulated during reproductive years
• Earlier onset of menopause (1–2 years on average)
• Lower estrogen levels throughout perimenopause
• Reduced calcium absorption and vitamin D status

A woman who has smoked a pack a day since age 20 and enters menopause at 50 may have bone density equivalent to that of a non-smoking 55-year-old — effectively aging her skeleton by 5 years through the combined effects of smoking on her bones.

When Does Bone Start Recovering After Quitting?

This is the most important question for current smokers, and the answer is encouraging — recovery is real and measurable, though it takes time.

Studies following former smokers show:

• First 1–2 years: Bone turnover markers normalize toward non-smoker levels. Osteoblast activity increases. The rate of bone loss slows and may stop. This is not yet visible as density increase on a DEXA scan.
• 2–5 years post-cessation: Measurable improvement in bone mineral density at the lumbar spine begins to appear in some studies. Estrogen levels in women rise toward non-smoker levels within the first year of quitting.
• 5–10 years: Former smokers' bone density converges toward non-smoker levels. Hip fracture risk decreases progressively. A 2020 meta-analysis found that 10 years after quitting, hip fracture risk in former smokers was not significantly different from never-smokers.
• The caveat: Recovery depends heavily on age at cessation, duration of smoking, and nutritional/exercise habits after quitting. Someone who quits at 45 has more recovery potential than someone who quits at 65, simply because bone remodelling capacity decreases with age.

Smoking and Osteoporosis Medications

If you have osteoporosis and are taking medication, smoking affects treatment in specific ways:

Bisphosphonates (alendronate / Fosamax, risedronate / Actonel)

No direct pharmacokinetic interaction with smoking, but smoking reduces the baseline bone density that these drugs are trying to protect. Studies suggest bisphosphonates are modestly less effective in smokers — possibly because smoking continues to suppress osteoblast activity even as bisphosphonates reduce osteoclast activity, limiting the net gain.

Denosumab (Prolia)

No known interaction. However, smokers are at higher fall risk (due to lower body weight, reduced muscle mass, and possible impaired balance), which limits the fracture-prevention benefit of all bone medications.

Hormone Therapy

Smoking and estrogen-containing hormone therapy combined increase cardiovascular risk, particularly for blood clots (venous thromboembolism). Health Canada and the Society of Obstetricians and Gynaecologists of Canada (SOGC) recommend caution with systemic HRT in current smokers, particularly oral estrogen. Transdermal (patch) estrogen carries lower clot risk and may be a preferable option for smokers who need HRT — discuss with your prescriber.

Anabolic Agents (teriparatide / Forteo, romosozumab / Evenity)

These work by stimulating new bone formation. Smoking directly suppresses osteoblast activity — the same cells these drugs are trying to activate. There is a biological rationale to expect reduced effectiveness in active smokers, though direct clinical trial data comparing outcomes in smokers vs. non-smokers on anabolic therapy is limited.

Canadian Cessation Resources

Quitting smoking is one of the most impactful things a person can do for their bone health — and there are free, evidence-based resources available across Canada:

Prescription Cessation Aids

Evidence-based pharmacotherapy roughly doubles quit success rates. Two prescription options are available in Canada:

• Varenicline (Champix): Most effective single agent for smoking cessation. Covered under many provincial drug plans (check your provincial formulary). Note: Champix was temporarily withdrawn in 2021 due to nitrosamine impurities; it re-entered the Canadian market in 2022. Confirm availability with your pharmacist.
• Bupropion (Zyban): An antidepressant that reduces nicotine cravings. Widely available and covered in most provincial formularies.
• Nicotine Replacement Therapy (NRT): Patches, gum, lozenges, and inhalers. Available over the counter; some provincial programs cover costs for eligible residents.

Putting It Together: Bone-Specific Actions for Smokers

Whether you're currently smoking, just quit, or quit years ago:

1. Ask your doctor about a DEXA bone density scan. Smoking history is a recognized indication for earlier screening, especially in women nearing or past menopause.
2. Supplement vitamin D year-round. Health Canada recommends 600 IU/day for adults under 70 and 800 IU for those over 70, but many bone health specialists recommend 1,000–2,000 IU for smokers and former smokers.
3. Ensure calcium intake of 1,200 mg/day through food and supplements combined.
4. Do weight-bearing and resistance exercise. Exercise is one of the few ways to actively stimulate new bone formation — see our bone density exercise guide.
5. If you take HRT, discuss your smoking history with your prescriber to ensure the form and dose are appropriate.
6. Review the broader landscape of osteoporosis risk factors — smoking rarely acts alone.